相关实验视频

Updated: May 29, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

对于子宫内膜癌的瘤免疫学和免疫疗法

Kosuke Murakami¹, Shiki Takamura², Kazuhiro Kakimi³

¹Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.

Expert opinion on investigational drugs

|February 6, 2025

概括

免疫检查点抑制剂 (ICI) 与化疗相结合,对晚期子宫内膜癌显示有前途. PARP 抑制剂可能会增强 ICI 疗效,特别是在特定的瘤类型和肥胖患者中,建议个性化治疗策略.

科学领域:

妇科瘤学妇科瘤学
免疫治疗是一种免疫疗法.
分子瘤学分子瘤学

背景情况:

晚期或复发性子宫内膜癌的治疗疗效正在通过免疫检查点抑制剂 (ICI) 和多 (ADP-ribose) 聚合酶 (PARP) 抑制剂得到改善.
这些治疗效果和个性化治疗方法的潜在机制仍然不清楚.

研究的目的:

审查从子宫内膜癌III期临床试验中的子组分析.
探索肥胖,PARP抑制剂和子宫内膜癌瘤免疫之间的相互作用.
为优化ICI和PARP抑制剂治疗提供见解.

主要方法:

对2000年至2024年间出版的文献进行叙事审查.
从关键子宫内膜癌临床试验 (NRG-GY018,RUBY,AtTEnd,KEYNOTE-B21,DUO-E) 中对子组数据的有针对性的解释.
分析肥胖,PARP抑制剂和瘤免疫之间的关系.

主要成果:

化疗加上ICI对于不匹配修复缺陷 (dMMR) 的子宫内膜癌是有效的.
化疗加上ICI和PARP抑制剂可以通过激活cGAS-STING通路,使TP53-异常或血清性癌症类型受益.
肥胖可能会提高ICI的疗效,这可能解释区域差异;可测量的疾病和生活方式因素也可能影响结果.

结论:

个性化子宫内膜癌治疗可以通过了解ICI和PARP抑制机制来获取信息.
PARP 抑制剂通过cGAS-STING通路增强ICI疗效,有利于特定的瘤亚型.
肥胖,疾病状况和生活方式因素是优化治疗反应的关键因素.

关键词:

这是子宫内膜癌的癌症.这是一种PARP抑制剂.刺痛是一种刺痛.dMMR 是一个MMR.免疫检查点抑制剂免疫检查点抑制剂免疫疗法免疫疗法肥胖肥胖肥胖肥胖肥胖肥胖肥胖肥胖

更多相关视频

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...